LONGEVA.

KLOW: side effects and evidence limits

The KLOW listing describes a lyophilized mixture of BPC-157 10 mg, GHK-Cu 50 mg, TB-500 10 mg and KPV 10 mg [1]. These component names do not verify equivalence to the cited study materials; the inspected specifications do not establish the exact TB-500 sequence.

The inspected plasma-tripeptide/copper abstract describes nanomolar cell-culture experiments, including toxic responses in some settings [2]. Another abstract concerns KPV in human-derived cell lines and mice with induced colitis, receiving KPV in drinking water [3]. These are not studies administering KLOW to people.

Cell toxicity and mouse inflammation measures are not human adverse-reaction frequencies. The inspected abstracts describe individual components and do not establish clinical safety of this mixture. Component event rates cannot be added or transferred to KLOW; formulation and fragment equivalence remain unresolved [1–3].

What the studies reported

EffectModel or participantsHow often or as describedSource
Toxic responses in some settingsCell cultures, nanomolar experiments with the plasma tripeptide and copper (the GHK-Cu component)Described in some settings; cell toxicity is not a human adverse-reaction frequency[2]
Data on the KPV componentHuman-derived cell lines and mice with induced colitis, KPV in drinking waterThe KLOW mixture was not administered to people; component event rates cannot be added or transferred to the mixture[1–3]

References

  1. Longeva (2026). KLOW Blend https://longeva.bio/ua/product/klow.
  2. Pickart L et al. (1980). Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells. https://pubmed.ncbi.nlm.nih.gov/7453802/ doi:10.1038/288715a0.
  3. Dalmasso G et al. (2008). PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. https://pubmed.ncbi.nlm.nih.gov/18061177/ doi:10.1053/j.gastro.2007.10.026.